- Home
- EYPT vs MGTX Comparison
EYPT vs MGTX Comparison
Compare EYPT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- MGTX
- Stock Information
- Founded
- EYPT 1987
- MGTX 2015
- Country
- EYPT United States
- MGTX United States
- Employees
- EYPT N/A
- MGTX N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYPT Industrials
- MGTX Health Care
- Exchange
- EYPT Nasdaq
- MGTX Nasdaq
- Market Cap
- EYPT 741.0M
- MGTX 670.2M
- IPO Year
- EYPT 2005
- MGTX N/A
- Fundamental
- Price
- EYPT $14.00
- MGTX $8.83
- Analyst Decision
- EYPT Strong Buy
- MGTX Strong Buy
- Analyst Count
- EYPT 6
- MGTX 2
- Target Price
- EYPT $25.83
- MGTX $24.00
- AVG Volume (30 Days)
- EYPT 1.1M
- MGTX 362.5K
- Earning Date
- EYPT 11-06-2025
- MGTX 11-12-2025
- Dividend Yield
- EYPT N/A
- MGTX N/A
- EPS Growth
- EYPT N/A
- MGTX N/A
- EPS
- EYPT N/A
- MGTX N/A
- Revenue
- EYPT $51,898,000.00
- MGTX $37,917,000.00
- Revenue This Year
- EYPT N/A
- MGTX $144.79
- Revenue Next Year
- EYPT N/A
- MGTX $168.58
- P/E Ratio
- EYPT N/A
- MGTX N/A
- Revenue Growth
- EYPT 2.99
- MGTX 366.84
- 52 Week Low
- EYPT $3.91
- MGTX $3.97
- 52 Week High
- EYPT $14.91
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- EYPT 58.99
- MGTX 68.23
- Support Level
- EYPT $13.00
- MGTX $8.20
- Resistance Level
- EYPT $14.04
- MGTX $8.68
- Average True Range (ATR)
- EYPT 0.93
- MGTX 0.41
- MACD
- EYPT -0.08
- MGTX 0.05
- Stochastic Oscillator
- EYPT 62.87
- MGTX 92.79
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.